Ocular Drug Delivery Systems Barriers and Application of Nanoparticulate Systems

Drug discovery for ocular diseases has taken great strides in the last two decades. From cornea to choroid, new drugs have been formulated to address a great variety of ocular diseases. Yet without good drug delivery systems, these drugs are less effective than they might be or could even cause serious side effects. Ocular Drug Delivery Systems: Barriers and Application of Nanoparticulate Systems presents research on the development of currently marketed devices and recent trends in the topical delivery of drugs to the posterior of the eye. With contributions from leading pharmaceutical researchers and industry experts, eye researchers, surgeons, pharmacologists from academia, the National Eye Institute, and leading ophthalmic companies such as Pfizer, Allergan, and Novartis, the book presents the state of the art in the use of nanoparticles in ocular drug delivery systems and also sets the stage for future developments.This volume provides both a current evaluation and a future roadmap for developments in ocular drug delivery. The subjects range from biological needs to material challenges and finally to clinical applications for improving drug delivery for conditions where treatments already exist. It also explores areas where effective drugs may be currently available but yet need a safe, efficient, and efficacious delivery vehicle.

Basic ConsiderationsNanoparticle-Based Therapeutics: An OverviewDeepak Thassu, Kris Holt, and Gerald J. ChaderEye Anatomy, Physiology and Ocular Barriers: Basic Considerations for Drug DeliveryGerald J. Chader and Deepak ThassuAnimal Models to Evaluate Ocular Nanoparticular Drug Delivery SystemsVinson M. Wang, Jingsheng Tuo, and Chi-Chao ChanComputer Modeling for Ocular Drug DeliveryPaul J. MisselChallenges in the Development of Nanotechnology-Based Ophthalmic SystemsBanu S. Zolnik, Sheriza Baksh, and Nakissa SadriehOcular BarriersBlood–Retinal Barrier: The FundamentalsRosa Fernandes, Andreia Gonçalves, and José Cunha-VazBarriers to Transscleral Drug Delivery to the RetinaAlexandra Almazan, Susan S. Lee, Aron D. Ross, and Michael R. RobinsonOcular Compartment Drug DeliveryDrug Delivery to the Vitreous HumorFrancine Behar-CohenTransscleral and Suprachoroidal Drug DeliveryDamian E. Berezovsky and Henry F. EdelhauserProtein Drug Delivery to Retina and ChoroidHongwen M. Rivers and Patrick M. HughesTransscleral Drug Delivery to the Posterior Segment of the EyeBernard F. Godley, Cheryl L. Rowe-Rendleman, Ed Kraft, and Gabriella KulpDrug Delivery to the Suprachoroidal SpaceSung Won Cho and Timothy W. OlsenUse of Nanoparticles in the Treatment of Age-Related Macular Degeneration, Glaucoma, and Other Degenerative Retinal DiseasesMarco A. Zarbin, Carlo Montemagno, James F. Leary, and Robert RitchDrug Delivery SystemsDrug Molecule Characteristics, Drug Delivery Strategies and Their Impact on Ophthalmic Drug Delivery to Anterior versus Posterior SegmentsKay D. RittenhouseSurface Modulation of NanoparticlesDeepak Thassu and Kris HoltNanoparticles for the Treatment of Retinal DiseasesAmin Famili and Uday B. KompellaGene-Based Medicine for Ocular DiseasesShannon M. Conley and Muna I. NaashStealth-Type Polymeric Nanoparticles with Encapsulated Betamethasone Phosphate for Treatment of Intraocular InflammationTsutomu Sakai, Tsutomu Ishihara, and Megumu HigakiTechnology and Materials DevelopmentNanotechnology-Guided Imaging of Retinal Vascular DiseaseJoshua R. Trantum and Ashwath JayagopalPhotoresponsive Polymers for Ocular Drug DeliveryLaura A. Wells and Heather SheardownNanosuspensions in Ocular Drug Delivery SystemsHimanshu Bhattacharjee and Sonia Bedi

Deepak Thassu is the Vice President of Pharmaceutical Development at Pharmanova, Inc., in Victor, New York. Gerald Chader is Chief Scientific Officer of the Doheny Retina Institute at USC Medical School in Los Angeles.